QC
VKTX icon

Quent Capital’s Viking Therapeutics VKTX Stock Holding History

Quent Capital’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.9K Sell
120
-15
-11% -$482 ﹤0.01% 1314
2025
Q4 		$4.75K Buy
135
+43
+47% +$1.52K ﹤0.01% 1282
2025
Q3 		$2.42K Buy
+92
New +$2.75K ﹤0.01% 1239
2025
Q2 		– Sell
-51
Closed -$1.23K – 1209
2025
Q1 		$1.23K Hold
51
– – ﹤0.01% 1188
2024
Q4 		$2.05K Buy
51
+1
+2% +$57 ﹤0.01% 1169
2024
Q3 		$3.17K Buy
+50
New +$2.93K ﹤0.01% 1176

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Quent Capital's VKTX Position: Q1 2026 in Review

Quent Capital reduced its Viking Therapeutics (VKTX) stake by 11% in Q1 2026, selling an estimated $482 and leaving 120 shares worth $3.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1314.

Quent Capital first reported a position in VKTX in Q3 2024 and has held it in 6 quarters since. The position peaked at $4.75K in Q4 2025. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Quent Capital held 120 shares of Viking Therapeutics worth $3.9K as of Q1 2026.
  • Quent Capital sold 15 Viking Therapeutics shares in Q1 2026, an estimated $482.
  • Viking Therapeutics made up ﹤0.01% of Quent Capital's portfolio in Q1 2026, its #1314 holding.
  • Quent Capital first reported a position in Viking Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • Quent Capital's Viking Therapeutics position peaked at $4.75K in Q4 2025.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Quent Capital's 13F filing for Q1 2026, filed 28 Apr 2026.